MARIE LOERA: Open Payments
NPI 1346533668 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,092 in 156 payments from 19 companies in 2025. Trend: 2023 $2,840 · 2024 $2,168 · 2025 $4,092
Food & beverage: $4,058Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $790 |
| ARS Pharmaceuticals Operations, Inc. | 36 | $737 |
| GlaxoSmithKline, LLC. | 24 | $556 |
| GENZYME CORPORATION | 7 | $408 |
| Regeneron Healthcare Solutions, Inc. | 12 | $380 |
| SANOFI-AVENTIS U.S. LLC | 8 | $216 |
| Galderma Laboratories, L.P. | 7 | $171 |
| Grifols USA, LLC | 10 | $171 |
| Alkermes, Inc. | 1 | $130 |
| Amgen Inc. | 4 | $89 |
Products named: DUPIXENT, NEFFY, TEZSPIRE, FASENRA, NUCALA, BREZTRI, TRELEGY ELLIPTA, NEMLUVIO.
Industry payments across TX — which companies pay providers there.
